Rani Therapeutics Q3 net loss $12.7M; cash $30.4M extended into Q3 2025

Rani Therapeutics Holdings, Inc.

2024-Q3 EPS reported -$0.78

Net loss of $12.7M for Q3 2024, compared to $18.3M in Q3 2023; includes $4.1M stock-based comp.
Cash, equivalents and marketable securities $30.4M as of Sep 30, 2024; runway extended into Q3 2025.
Completed two equity offerings for total gross proceeds of ~$20.0M in July and October 2024.
New preclinical PK data supports oral delivery of GLP-1/GIP/glucagon triagonist via RaniPill platform.
Phase 1 trial of RT-114 (GLP-1/GLP-2 dual agonist) for obesity expected to start in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.